The purity of recombinant hCCL3 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hCCL3 and staining overnight with Coomassie Blue.Learn more about how we get our images
hCCL3-induced migration of THP-1 cells was asssessd. THP-1 cells were incubated in a 96-well transwell plate with increasing concentrations of hCCL3 in the bottom chamber. After 2 hr, the number of THP-1 cells that migrated to the bottom chamber of the transwell was quantified by measuring DNA content using a fluorescent dye.Learn more about how we get our images
Recombinant human CCL3 (hCCL3) Ala27-Ala92 (Accession #NP_002974) was produced in E. coli at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hCCL3. All lots are greater than 98% pure.
Recombinant hCCL3 does not have a Met on the amino terminus and has a calculated MW of 7445. DTT-reduced and non-reduced protein migrate as 8 kDa polypeptides. The expected amino-terminal ADTPT of recombinant hCCL3 was verified by amino acid sequencing.
The activity of hCCL3 was determined using a THP-1 cell migration assay. The ED50 of each lot is between 0.5-1.2 ng/ml.
Less than 0.01 ng endotoxin/1 μg hCCL3.
With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hCCL3. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
CCL3, also know as MIP-1-α, or LD78α, is an 8 kDa member of the C-C family of chemokines, which play key roles in immune surveillance, inflammation, and infection (1). CCL3 shares 68% amino acid identity with CCL4 (MIP-1-β) and 94% amino acid identity with LD78β (1). CCL3 is produced by activated monocytes, activated macrophages, NK cells, and T cells among others (1). There are two receptors for CCL3: CCR1 and CCR5 (1). CCL3 inhibits R5 HIV-1 infection by competing with the virus for its co-receptor, CCR5 (1). CCL3 polymorphisms are associated with risk for the development of rheumatoid arthritis and ulcerative colitis (2,3).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.